Two phase III trials have shown that prolonging chemotherapy duration improves outcome in patients with nonsquamous non-small-cell lung cancer. Pemetrexed versus placebo, and pemetrexed–bevacizumab versus bevacizumab was tested in patients without disease progression after pemetrexed–cisplatin treatment. Biomarker-directed chemotherapy and/or targeted therapy could further improve treatment outcomes for patients with lung cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Paz-Ares, L. et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 13, 247–255 (2012).
Barlesi, F. et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2012.42.3749.
Paz-Ares, L. G. et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2012.47.1102.
Karnofsky, D. A., Abelmann, W. H,, Craver, L. F. & Burchenal, J. H. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma Cancer 1, 634–656 (1948).
Westeel, V. et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J. Natl Cancer Inst. 97, 499–506 (2005).
Scagliotti, G. V. et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26, 3543–3551 (2008).
Nicolson, M. C. et al. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J. Thorac. Oncol. 8, 930–939 (2013).
Rosell, R., Bivona, T. G. & Karachaliou, N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet (in press).
Dominguez, C. L. et al. Diacylglycerol kinase alpha is a critical signaling node and novel therapeutic target in glioblastoma and other cancers. Cancer Discov. 3, 782–797 (2013).
Pullamsetti, S. S. et al. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene 32, 1121–1134 (2013).
Acknowledgements
The authors acknowledge support from La Caixa Foundation and Redes Temáticas de Investigación en Cáncer (RD12/0036/0072).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Rosell, R., Karachaliou, N. Maintenance therapy and precision medicine in NSCLC. Nat Rev Clin Oncol 10, 549–550 (2013). https://doi.org/10.1038/nrclinonc.2013.152
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2013.152
This article is cited by
-
ANKRD49 promotes the metastasis of NSCLC via activating JNK-ATF2/c-Jun-MMP-2/9 axis
BMC Cancer (2023)
-
RASSF9 promotes NSCLC cell proliferation by activating the MEK/ERK axis
Cell Death Discovery (2021)
-
Effect of etoposide plus thalidomide as maintenance therapy on progression-free survival of elderly patients with advanced non-small cell lung cancer
Oncology and Translational Medicine (2017)
-
Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation
BMC Cancer (2016)
-
Elevated expression of HMGA1 correlates with the malignant status and prognosis of non-small cell lung cancer
Tumor Biology (2015)